# A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

> **NCT04857892** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 41 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GSK3640254
- **DRUG:** DTG
- **DRUG:** GSK3640254/DTG

## Key facts

- **NCT ID:** NCT04857892
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-21
- **Primary completion:** 2021-09-10
- **Final completion:** 2021-09-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857892, "A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04857892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*